Ingalls & Snyder LLC’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Ingalls & Snyder LLC’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-13,800	Closed	-$25K	–	432
2018 Q1	$25K	Buy	13,800 +3,800	+38%	+$8.03K	﹤0.01%	398
2017 Q4	$22K	Hold	10,000	–	–	﹤0.01%	393
2017 Q3	$29K	Sell	10,000 -2,952	-23%	-$10.1K	﹤0.01%	355
2017 Q2	$58K	Hold	12,952	–	–	﹤0.01%	356
2017 Q1	$60K	Hold	12,952	–	–	﹤0.01%	395
2016 Q4	$79K	Buy	12,952 +2,952	+30%	+$15.4K	﹤0.01%	393
2016 Q3	$55K	Hold	10,000	–	–	﹤0.01%	407
2016 Q2	$38K	Hold	10,000	–	–	﹤0.01%	418
2016 Q1	$27K	Hold	10,000	–	–	﹤0.01%	354
2015 Q4	$56K	Sell	10,000 -16	-0.2%	-$98	﹤0.01%	360
2015 Q3	$53K	Buy	10,016 +16	+0.2%	+$124	﹤0.01%	353
2015 Q2	$83K	Hold	10,000	–	–	﹤0.01%	361
2015 Q1	$46K	Hold	10,000	–	–	﹤0.01%	372
2014 Q4	$30K	Hold	10,000	–	–	﹤0.01%	369
2014 Q3	$27K	Hold	10,000	–	–	﹤0.01%	375
2014 Q2	$40K	Buy	+10,000	New	+$42.5K	﹤0.01%	378

Other funds holding SGYP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Ingalls & Snyder LLC's SGYP Position: Q2 2018 in Review

Ingalls & Snyder LLC sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q2 2018, closing a stake of 13,800 shares — an estimated $25K sold.

Ingalls & Snyder LLC first reported a position in SGYP in Q2 2014 and held it in 16 quarters. The position peaked at $83K in Q2 2015. 136 funds tracked by Wall St. Rank hold SGYP as of Q2 2018.

Ingalls & Snyder LLC reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q2 2018 after selling out during the quarter.
Ingalls & Snyder LLC sold 13,800 Synergy Pharmaceuticals, Inc Common Stock shares in Q2 2018, an estimated $25K.
Ingalls & Snyder LLC first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2014 and held it in 16 quarters.
Ingalls & Snyder LLC's Synergy Pharmaceuticals, Inc Common Stock position peaked at $83K in Q2 2015.
136 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q2 2018.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2018, filed 10 Aug 2018.